- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2017
- Public Summary Document (PSD) July 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2017 PBAC Meeting - Word
Eculizumab – July 2017
Eculizumab: Solution concentrate for I.V.infusion 300 mg in 30 mL; Soliris®
Last updated
27 October 2017